HCPCS Code J2327: Injection, Risankizumab-rzaa, Intravenous, 1 mg

Learn about the HCPCS code J2327 for "injection, risankizumab-rzaa, intravenous, 1 mg" through this short guide.

## **What is the HCPCS code J2327 for?** The HCPCS code J2327 is meant to designate the provision of a risankizumab-rzaa intravenous injection, specifically per 1 mg dose. This is sometimes referred to as a Skyrizi risankizumab-rzaa injection. This specific injection is meant to treat severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderately to severely active Crohn's disease. What this medicine does is to reduce inflammation and the effects of these conditions on the patient. Depending on the patient's condition, the number of injections across a certain span of time will vary, and it'll either be administered intravenously.

## **Documentation requirements for J2327** As with any HCPCS code, you must have sufficient documentation for J2327 based on the guidelines of your insurer. Here are examples of what might typically be asked of you: - The full name of the patient - The full names and credentials of the professionals handling the patient - The name of the facility where the injection was administered - Relevant information and indications related to the patient's medical history to justify medical necessity - The drug name, strength, and dosage administered - Number of billing units - Start and stop times of the injection, especially if it was intravenous - Provider order including frequency of the injection - Prior authorization - Documentation of treatment and management plans that have been implemented (they should follow standard procedures set by the likes of AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease, or something like ECCO Guidelines on Therapeutics in Crohn's Disease - Lot number, manufacturer, and expiration date of the injection

## **Billing requirements for J2327** Besides the documentation requirements above, please make sure to take note of or have the following: - 1 mg = 1 unit. Please report the total number of units corresponding to total mg administered - Use the necessary ICD code based on the patient's condition - Use the necessary CPT code because on the route of injection (96365 if you administered the injection via IV) - Use either of two modifiers: JW if there's unused medication in a vial (wastage), or JZ if there's no unused medication ### **Sample ICD codes you can use** Remember that this medicine deals with problems like severe ulcerative colitis, plaque psoriasis, Crohn's disease, etc. Here are examples of ICD codes you can use: - **K50.111** - Crohn's disease of large intestine with rectal bleeding - **K50.012** - Crohn's disease of small intestine with intestinal obstruction - **K50.913** - Crohn's disease, unspecified, with fistula - **K50.811** - Crohn's disease of both small and large intestine with rectal bleeding - **K51.911** - Ulcerative colitis, unspecified with rectal bleeding - **K51.211** - Ulcerative (chronic) proctitis with rectal bleeding - **K51.012** - Ulcerative (chronic) pancolitis with intestinal obstruction - **K51.313** - Ulcerative (chronic) rectosigmoiditis with fistula

## **Other similar codes** - **J2323** - Injection, natalizumab, 1 mg - **J2325** - Injection, nesiritide, 0.1 mg - **J2329** - Injection, ublituximab-xiiy, 1mg - **J2350** - Injection, ocrelizumab, 1 mg - **J2351** - Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq

Frequently asked questions

It depends on their condition and your findings. Some are required to take two additional shots 4 weeks after the first one. Some have to take it once every four weeks until three doses have been administered.

It depends. If it's administered via IV, it'll take 1 or 2 hours.

Yes, but billing depends on payer coverage. Combination therapy requires documentation of medical necessity and separate coding for each agent.